Neoadjuvant Therapy for Resectable Pancreatic Cancer: An Evolving Paradigm Shift
Open Access
- 17 October 2019
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 9, 1085
Abstract
Non-metastatic pancreatic adenocarcinoma (PDAC) is associated with a high rate of recurrence and lethality. In addition, less than half of all patients are able to complete systemic therapy after curative-intent pancreatectomy. With its well-known potential benefits, this report highlights the current prospective data relevant to the use of neoadjuvant systemic therapy in resectable PDAC. Recently, there have been numerous reports, many of which consist of long-awaited multi-intuitional trial data evaluating the use of neoadjuvant systemic chemotherapy in non-metastatic PDAC as well as the use of combination chemotherapy regimens in the adjuvant setting. Currently, recommended guidelines for neoadjuvant systemic therapy only exist for borderline-resectable and locally-advanced disease. Given the plethora of new data, there has been a shift in the paradigm of how resectable pancreatic cancer is treated at certain centers across the world. This review highlights the relevant available data from recent sentinel prospective trials and how they relate to the systemic treatment of resectable PDAC in the neoadjuvant setting.Keywords
This publication has 27 references indexed in Scilit:
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineNew England Journal of Medicine, 2013
- Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic CancerJAMA, 2013
- Neoadjuvant therapy in resectable pancreatic cancer: A critical reviewCancer Treatment Reviews, 2013
- Neoadjuvant Therapy of Pancreatic Cancer: The Emerging Paradigm?The Oncologist, 2012
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer ResectionJAMA, 2010
- A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic CancerBritish Journal of Cancer, 2009
- S-1: a promising new oral fluoropyrimidine derivativeExpert Opinion on Investigational Drugs, 2009
- A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic CancerNew England Journal of Medicine, 2004
- Pancreatic CancerArchives of Surgery, 1985